Recombinant Human B1 bradykinin receptor (BDKRB1)

What is the B1 bradykinin receptor and what distinguishes it from other bradykinin receptors?

The bradykinin B1 receptor (BDKRB1) is an inducible G-protein-coupled receptor encoded by the BDKRB1 gene in humans. Unlike the constitutively expressed B2 receptor, the B1 receptor is specifically induced or upregulated at sites of inflammation or injury . Structurally, the B1 receptor is a 353-amino acid protein with G-protein-coupled receptor characteristics, sharing approximately 36% sequence identity with the B2 bradykinin receptor . The principal ligand for the B1 receptor is bradykinin, a 9-amino acid peptide generated during pathophysiologic conditions such as inflammation, trauma, burns, shock, and allergic reactions .

What are the primary agonists and antagonists for the BDKRB1 receptor?

The B1 receptor demonstrates distinct pharmacological properties compared to the B2 receptor. The cloned B1 bradykinin receptor exhibits high-affinity binding for des-Arg10-kallidin (a selective B1 receptor agonist) and low affinity for bradykinin . Classical agonists include bradykinin1-8 (bradykinin with the first 8 amino acids) . Regarding antagonists, [des-Arg10,Leu9]kallidin effectively displaces des-Arg10-kallidin from the cloned receptor, while B2 receptor antagonists like Hoe-140 do not demonstrate significant binding . Two major classes of small-molecule B1 antagonists have been developed: arylsulfonamide-based and biphenyl-based antagonists .

How is BDKRB1 expression regulated at the cellular level?

The B1 receptor undergoes de novo synthesis following tissue injury, making it distinct from many constitutively expressed receptors . The up-regulation of B1 receptor expression involves nuclear factor-kappaB (NF-κB) activation, as evidenced by the inhibitory effect of pyrrolidine dithiocarbamate (an inhibitor of NF-κB activation) on B1 receptor sensitization . Tumor necrosis factor-alpha (TNF-α) potentiates B1 receptor responses without modifying the maximal response to des-Arg9-BK . Experimental evidence using transcription and translation inhibitors (actinomycin D and cycloheximide, respectively) confirms that de novo synthesis of a transmembrane glycoprotein is essential for B1 receptor up-regulation . Notably, the time required for synthesis, trafficking, and functional membrane expression of this receptor is less than 1 hour, indicating an efficient induction pathway .

What are the optimal cell lines and expression systems for studying recombinant BDKRB1?

For recombinant expression of human BDKRB1, several expression systems have proven effective. Chinese hamster ovary (CHO-K1) cells represent a well-established host cell line for expressing recombinant human B1 receptors . Additionally, human embryonic lung fibroblasts have been successfully used for expression cloning of the human B1 bradykinin receptor . When preparing membrane preparations for binding assays, cells expressing recombinant or endogenous receptors can be selected for optimal performance .

The expression of recombinant BDKRB1 typically couples to Gq/G11 signaling pathways, leading to increased cytosolic calcium ion concentration upon receptor activation . These membrane preparations are suitable for various high-throughput screening applications, including radioligand binding assays using either proximity methods (such as FlashPlate) or classical filtration methods .

How can researchers effectively measure BDKRB1 activation and signaling?

When studying BDKRB1 signaling, several experimental approaches have proven effective:

• Calcium mobilization assays: The photoprotein aequorin can be utilized as an indicator of B1 receptor agonist-mediated Ca²⁺ mobilization, as demonstrated in expression studies using Xenopus laevis oocytes .

• Radioligand binding assays: 3H-labeled [des-Arg10]kallidin binding provides a reliable method for assessing B1 receptor expression and ligand affinity. Competition binding assays with known reference agonists and antagonists allow determination of receptor affinity (Ki) .

• Functional membrane expression: Concentration-response curves to des-Arg9-BK (a selective B1 receptor agonist) can be performed after appropriate incubation periods to assess receptor functionality .

• Molecular signaling pathway analysis: Downstream signaling events can be monitored, such as the MEK1-ERK1/2-NF-κB pathway activation that follows BDKRB1-mediated calcium influx in certain cell types .

What methodological approaches are recommended for studying BDKRB1 in disease models?

When investigating BDKRB1 in disease models, researchers have successfully implemented the following methodological approaches:

• RNA interference (RNAi): Knocking down BDKRB1 expression using siRNA has proven effective for evaluating the receptor's role in pathological processes. In glioblastoma studies, application of BDKRB1 siRNA to human U87 MG cells led to substantial reduction in levels of associated proteins like AQP4 .

• Wound-healing and invasion assays: These techniques can assess the functional consequences of BDKRB1 modulation. In glioblastoma cells, exposure to bradykinin (100 nM for 24h) triggered 2.6-fold wound-healing activity, while knocking down BDKRB1 caused a 60% reduction in bradykinin-induced wound-healing .

• Pharmacological interventions: Various inhibitors targeting components of the signaling pathway (e.g., pyrrolidine dithiocarbamate for NF-κB inhibition) help dissect the mechanisms involved in BDKRB1-mediated effects .

How does BDKRB1 contribute to inflammatory and pain pathways?

The B1 bradykinin receptor plays a significant role in inflammatory and pain pathways. Unlike the constitutively expressed B2 receptor, the B1 receptor is specifically induced or upregulated at inflammation or injury sites, making it particularly relevant to chronic inflammatory conditions . Receptor binding leads to increased cytosolic calcium concentration, ultimately resulting in chronic and acute inflammatory responses .

A substantial body of preclinical data supports the development of B1 antagonists as novel therapeutics for treating pain and inflammation . The inducible nature of the B1 receptor makes it a particularly attractive target, as it is primarily expressed at sites of tissue injury rather than in healthy tissues. This targeted expression profile potentially offers advantages in terms of specificity and reduced side effects compared to constitutively expressed receptors .

What is the relationship between BDKRB1 and aquaporin 4 (AQP4) in glioblastoma progression?

Research has revealed a significant relationship between BDKRB1 and aquaporin 4 (AQP4) in glioblastoma progression. The bradykinin-BDKRB1 axis regulates AQP4 gene expression in glioblastoma cells through a specific signaling cascade . Exposure to bradykinin induces AQP4 expression through BDKRB1-mediated calcium influx and subsequent activation of a MEK1-ERK1/2-NF-κB pathway .

Experimental data demonstrate that knocking down BDKRB1 using RNA interference concurrently decreases AQP4 mRNA expression and inhibits cell migration and invasion. Specifically, application of BDKRB1 siRNA to human U87 MG cells led to a 72% reduction in BDKRB1 expression and a corresponding 76% inhibition in bradykinin-induced AQP4 mRNA expression . Functionally, this resulted in a 60% reduction in bradykinin-induced wound-healing activity and significantly decreased cell invasion .

These findings suggest that the bradykinin-BDKRB1 axis and AQP4 could serve as precise targets for treating glioblastoma multiforme (GBM) patients, offering a potential therapeutic pathway to address this aggressive form of cancer .

What are the current challenges in developing selective BDKRB1 antagonists for therapeutic use?

The development of selective BDKRB1 antagonists presents several research challenges. While two major classes of small-molecule B1 antagonists (arylsulfonamide-based and biphenyl-based) have been disclosed, optimizing selectivity, potency, and pharmacokinetic properties remains challenging .

What are the optimal conditions for preparing BDKRB1 membrane fractions for binding studies?

When preparing BDKRB1 membrane fractions for binding studies, several technical considerations are important:

• Expression system selection: CHO-K1 cells have been successfully used as host cells for expressing recombinant human BDKRB1 . These cells provide a reliable platform for receptor expression and membrane preparation.

• Membrane preparation: Bradykinin B1 receptor membranes are typically prepared at concentrations of approximately 12.5 μg/μL protein, with standard units containing about 50 μg protein . This concentration is optimized for binding assays.

• Quality control testing: Every batch of receptor membrane preparations should undergo stringent quality control testing, including:

  • Saturation radioligand binding assays to determine receptor concentration (Bmax) and affinity (Kd)

  • Competition binding assays to determine affinity (Ki) against known reference agonists and antagonists

  • GTPγS data for Gi-coupled receptors

• Storage and handling: Membrane preparations are typically stored as frozen crude membrane preparations and should be handled according to specific protocols to maintain receptor integrity .

How can researchers differentiate between B1 and B2 receptor-mediated effects in experimental systems?

Differentiating between B1 and B2 receptor-mediated effects is crucial for understanding the specific contribution of each receptor subtype. Several approaches can be employed:

• Selective agonists and antagonists: Using receptor-selective compounds is the most direct approach. Des-Arg10-kallidin and des-Arg9-BK serve as selective B1 receptor agonists, while [des-Arg10,Leu9]kallidin functions as a B1 receptor antagonist . Conversely, B2 receptor antagonists like Hoe-140 (D-Arg0-[Hyp3,Thi5,D-Tic7,Oic8]bradykinin) do not bind to B1 receptors .

• Temporal expression patterns: The B1 receptor is inducible and upregulated following tissue injury or inflammation, whereas the B2 receptor is constitutively expressed . Experiments can exploit this difference by examining responses before and after inflammatory stimulation.

• Genetic approaches: RNA interference targeting BDKRB1 specifically can help isolate B1-mediated effects from those mediated by B2 receptors .

• Pharmacological induction and inhibition: The up-regulation of B1 receptors can be potentiated by tumor necrosis factor-alpha and inhibited by pyrrolidine dithiocarbamate (through NF-κB inhibition) . These tools provide additional mechanisms to manipulate B1 receptor expression selectively.

What are the critical variables that affect BDKRB1 expression and functionality in experimental systems?

Several critical variables significantly impact BDKRB1 expression and functionality in experimental systems:

• Inflammatory mediators: Tumor necrosis factor-alpha (TNF-α) potentiates B1 receptor responses, suggesting that inflammatory cytokines play a crucial role in regulating receptor expression and function .

• Nuclear factor-kappaB (NF-κB) activation: Pyrrolidine dithiocarbamate, an inhibitor of NF-κB activation, produces a concentration-dependent decrease in B1 receptor sensitization, indicating the importance of this transcription factor in receptor up-regulation .

• Transcription and translation: The de novo synthesis of B1 receptors is highly sensitive to transcription inhibitors (actinomycin D) and protein synthesis inhibitors (cycloheximide), highlighting the critical role of ongoing gene expression in maintaining receptor levels .

• Post-translational modifications: N-linked glycosylation appears to be essential for B1 receptor functionality, as the glycosylation inhibitor tunicamycin almost completely abolishes des-Arg9-BK-mediated responses .

• Incubation time and conditions: The time required for synthesis, trafficking, and functional membrane expression of the B1 receptor is less than 1 hour, indicating that experimental protocols need to account for this rapid induction and expression kinetics .

How does BDKRB1 contribute to vascular responses, and what experimental models best capture these effects?

The B1 bradykinin receptor plays a significant role in vascular responses, particularly under pathophysiological conditions. De novo synthesis of the B1 receptor is involved in the induction of vascular responses in the human umbilical vein (HUV), making this an important model system for studying B1-mediated vascular effects .

In HUV experimental models, concentration-response curves to des-Arg9-BK (a selective B1 receptor agonist) can be performed after appropriate incubation periods (typically 5 hours) to assess receptor functionality . This model has revealed several key aspects of B1 receptor pharmacology:

• Inflammatory potentiation: Tumor necrosis factor-alpha potentiates B1 receptor responses without modifying the maximal response to des-Arg9-BK, suggesting a role in receptor sensitization rather than increased expression .

• Signaling pathway: B1 receptor up-regulation in HUV involves nuclear factor-kappaB activation, as evidenced by the inhibitory effect of pyrrolidine dithiocarbamate .

• Protein synthesis requirements: The de novo synthesis of a transmembrane glycoprotein is essential for B1 up-regulation, with the time necessary for synthesis, trafficking, and functional membrane expression being less than 1 hour .

The HUV model therefore represents an excellent system for studying the induction and function of B1 receptors in vascular tissue, particularly in the context of inflammatory conditions.

What role does BDKRB1 play in glioblastoma progression, and how can this pathway be targeted therapeutically?

BDKRB1 plays a significant role in glioblastoma progression through several mechanisms:

• Regulation of AQP4 expression: The bradykinin-BDKRB1 axis regulates aquaporin 4 (AQP4) gene expression in glioblastoma cells. Exposure to bradykinin induces AQP4 expression by 3.6-fold in human U87 MG glioblastoma cells .

• Calcium signaling: This regulation occurs through BDKRB1-mediated calcium influx and subsequent activation of a MEK1-ERK1/2-NF-κB pathway .

• Enhanced cell migration and invasion: Exposure of human U87 MG glioblastoma cells to bradykinin (100 nM for 24h) triggers 2.6-fold wound-healing activity and 11-fold increased cell invasion .

• Validation through knockdown studies: Knocking down BDKRB1 using RNA interference causes a significant 76% inhibition in bradykinin-induced AQP4 mRNA expression, a 60% reduction in wound-healing activity, and decreased cell invasion .

These findings suggest that the bradykinin-BDKRB1 axis could be a precise target for treating glioblastoma multiforme (GBM) patients. Therapeutic approaches might include:

• Selective B1 receptor antagonists: Compounds that specifically target the B1 receptor could potentially inhibit the bradykinin-induced effects on glioblastoma progression .

• Interference with downstream signaling: Targeting components of the MEK1-ERK1/2-NF-κB pathway activated by BDKRB1 could provide alternative approaches to inhibit the effects of bradykinin on glioblastoma cells .

• Combined approaches: Given the complex nature of glioblastoma, combining BDKRB1-targeted therapies with other treatment modalities might offer more comprehensive therapeutic benefits.

What is the current evidence for BDKRB1 as a therapeutic target in pain and inflammatory conditions?

A substantial body of preclinical data supports the development of B1 receptor antagonists as novel therapeutics for treating pain and inflammation . The B1 receptor represents an attractive therapeutic target due to several key characteristics:

• Inducible expression: Unlike the constitutively expressed B2 receptor, the B1 receptor is specifically induced or upregulated at sites of inflammation or injury, potentially allowing for more targeted therapeutic intervention .

• Chronic inflammation role: B1 receptor binding leads to increased cytosolic calcium concentration, ultimately resulting in chronic and acute inflammatory responses .

• Available antagonists: Two major classes of small-molecule B1 antagonists have been disclosed: arylsulfonamide-based and biphenyl-based antagonists . These compounds provide a foundation for further therapeutic development.

• Established tools for evaluation: The necessary in vitro and in vivo drug discovery tools are currently available to evaluate novel B1 antagonists, facilitating the development and optimization of potential therapeutic compounds .

The selective induction of B1 receptors at sites of tissue injury makes them particularly attractive targets for chronic inflammatory conditions and persistent pain states. By targeting a receptor that is primarily expressed in pathological rather than normal physiological conditions, B1 antagonists might offer advantages in terms of reduced side effects compared to less selective anti-inflammatory approaches .